3/26
07:51 am
mplt
MapLight Therapeutics, Inc. GAAP EPS of -$2.47 [Seeking Alpha]
Low
Report
MapLight Therapeutics, Inc. GAAP EPS of -$2.47 [Seeking Alpha]
3/26
07:00 am
mplt
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Medium
Report
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
3/21
01:31 am
mplt
Low
Report
3/19
09:00 am
mplt
Maplight Therapeutics (MPLT) is now covered by Canaccord Genuity Group Inc.. They set a "buy" rating and a $35.00 price target on the stock.
Low
Report
Maplight Therapeutics (MPLT) is now covered by Canaccord Genuity Group Inc.. They set a "buy" rating and a $35.00 price target on the stock.
3/2
07:35 am
mplt
MapLight Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
MapLight Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
3/2
07:00 am
mplt
MapLight Therapeutics to Participate in Upcoming Investor Conferences
Low
Report
MapLight Therapeutics to Participate in Upcoming Investor Conferences
1/23
05:07 pm
mplt
Maplight Therapeutics (NASDAQ:MPLT) is now covered by analysts at
Weiss Ratings. They set a "sell (e)" rating on the stock.
Neutral
Report
Maplight Therapeutics (NASDAQ:MPLT) is now covered by analysts at
Weiss Ratings. They set a "sell (e)" rating on the stock.
1/9
07:41 am
mplt
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026 [Yahoo! Finance]
Medium
Report
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026 [Yahoo! Finance]
1/9
07:00 am
mplt
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026
Medium
Report
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026
1/5
07:00 am
mplt
MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis
Low
Report
MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis